CODX trades 78.0% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CODX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Co-Diagnostics, Inc. (CODX) has a Wall Street consensus price target of $6.00, based on estimates from 5 covering analysts. With the stock currently trading at $3.12, this represents a potential upside of +78.0%. The company has a market capitalization of $3M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CODX trades at a trailing P/E of -0.1x. Analysts expect EPS to grow +43.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
QDELQuidelOrtho Corporation | $842M | $12.37 | $12.25 | -10.4% | Hold | 7.4x | 15 |
FLGTFulgent Genetics, Inc. | $531M | $17.84 | $15.00 | -16.7% | Buy | — | 9 |
CLOVClover Health Investments, Corp. | $2.7B | $5.14 | $4.47 | -10.6% | Hold | 129.2x | 9 |
NVAXNovavax, Inc. | $1.5B | $9.00 | $18.00 | +97.2% | Buy | — | 23 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
IDXXIDEXX Laboratories, Inc. | $43.3B | $545.73 | $747.50 | +33.0% | Buy | 38.3x | 22 |
NEOGNeogen Corporation | $1.9B | $8.92 | $11.00 | +18.2% | Hold | 25.2x | 11 |
CHEKCheck-Cap Ltd. | $11M | $1.86 | — | — | — | — | — |
MESOMesoblast Limited | $2.0B | $15.50 | $11.50 | -20.0% | Buy | — | 11 |
BNGOBionano Genomics, Inc. | $4M | $1.15 | — | — | — | — | — |
Quick answers to the most common questions about buying CODX stock.
The consensus Wall Street price target for CODX is $6, representing 78.0% upside from the current price of $3.12. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CODX has a consensus rating of "Hold" based on 5 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies 78.0% upside from current levels.
CODX's current price is $3.12 with a consensus target of $6 (78.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for CODX, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
CODX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CODX stock forecast based on 5 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on CODX, with a "Hold" consensus rating and $6 price target (78.0% upside). 2 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CODX analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.